Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Cohort Study

NCT07762872 is registered in ClinicalTrials.gov with Junwei Hao, MD as lead sponsor.

NCT NCT07762872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07762872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Cohort Study
Lead sponsor
Junwei Hao, MD
Phase
Observational
Overall status
Recruiting
Start date
July 20, 2026
Completion date
January 20, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorders (nmosd)